• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Pharmaceutical Market
Pharmaceutical News
Pharmaceutical Stocks
  • Pharmaceutical Market
  • Pharmaceutical News
  • Pharmaceutical Stocks
pharmaceutical investing

Clementia Announces Pricing of IPO

Written by Bryan Mc Govern
|
Aug. 02, 2017 09:46AM PST

Clementia Pharmaceuticals announced the pricing of its initial public offering of 8,000,000 common shares at a price of $15 per share.

Clementia Pharmaceuticals (NASDAQ:CMTA) announced the pricing of its initial public offering of 8,000,000 common shares at a price of $15 per share.
As quoted in the press release:

The shares are expected to begin trading on The NASDAQ Global Select Market on August 2, 2017 under the ticker symbol “CMTA”.  In addition, Clementia has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 common shares at the initial public offering price, less underwriting discounts and commissions.  The offering is expected to close on August 7, 2017, subject to customary closing conditions.
Morgan Stanley & Co. LLC and Leerink Partners LLC are acting as book-running managers for the offering.  Wedbush Securities Inc. and BTIG, LLC are acting as co-managers for the offering.

Click here to read the full press release.

Source: www.newswire.ca

initial public offering public offering pharmaceutical investing
The Conversation (0)

Go Deeper

AI Powered
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

ForeScout Technologies Announces Pricing of Initial Public Offering

Latest News

Outlook Reports world

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
  • Energy
    • Uranium
    • Oil and Gas
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Industrial Metals
  • Agriculture
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Gaming
    • Cleantech
    • Emerging Tech
Life Science
    • Biotech
    • Cannabis
    • Psychedelics
    • Pharmaceuticals

Featured Pharmaceutical Investing Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES